The FDA has delivered a Commissioner's National Priority Voucher (CNPV) to Johnson & Johnson for a combination regimen based ...
The clinical trial industry is at a critical juncture where traditional methods are proving insufficient for managing today’s ...
Kyverna has previously reported positive midstage data with miv-cel in generalised myasthenia gravis (gMG), another ...
In a new pharmaphorum podcast, web editor Nicole Raleigh speaks with Benedict Cross, Chief Technology Officer at PhoreMost, a ...
Tolebrutinib was one of three oral BTK inhibitors that Sanofi acquired as part of its $3.7 billion buyout of Principia ...
The latest judgment follows another setback in its defence in October, when a California jury awarded an eye-watering $966 ...
At the same time, the Voluntary Scheme for Branded Medicines Pricing, Access and Growth (VPAG) has progressed, and the UK has ...
Among seven new medicines recommended for approval by the EMA's human medicine advisory committee at its latest meeting is ...
Omnichannel didn’t fail pharma. Our metrics did. In 2026, fixing that won’t be optional. It will separate teams that keep ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback